NCT06132945 - A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions

Metastatic Renal Cell CarcinomaBrain Metastases

Interventions

DRUG

Cabozantinib

Cabozantinib (40 mg PO daily)

DEVICE

Nivolumab

Nivolumab (480 mg IV Day 1)

RADIATION

Stereotactic Radiosurgery (SRS)

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale